Form 4: Royalty Pharma EVP Sells Over 110K Shares

Royalty Pharma's EVP of Investments & CLO, George W. Lloyd, sold 110,000 Class A Ordinary Shares in pre-planned transactions totaling approximately $4.24 million.

Summary

• George W. Lloyd, Executive Vice President, Investments & Chief Legal Officer of Royalty Pharma plc (RPRX), reported sales of Class A Ordinary Shares.
• A total of 110,000 shares were sold over two days: 79,346 shares on December 17, 2025, and 30,654 shares on December 18, 2025.
• The sales were executed at weighted average prices of $38.5688 per share on December 17, 2025, and $38.4959 per share on December 18, 2025.
• All reported transactions were conducted under a Rule 10b5-1 plan adopted by Mr. Lloyd on August 20, 2025.
• Following these transactions, Mr. Lloyd's direct beneficial ownership of Class A Ordinary Shares is 0, while indirect holdings through various entities total 779,915.19 shares.
• Mr. Lloyd also holds limited partnership interests in RPI US Partners 2019, LP, exchangeable into 7,527,320 Class A Ordinary Shares, and Class E Ordinary Shares of Royalty Pharma Holdings Ltd (RPH), exchangeable into 1,944,471 Class A Ordinary Shares, subject to vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the execution under a pre-planned 10b5-1 plan mitigates concerns that the sales are based on new, undisclosed negative information. It represents a planned liquidity event for the executive.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 plan, adopted on August 20, 2025, indicating a planned liquidity event rather than a reaction to new, undisclosed negative information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Future Outlook

NA

Industry Context

This insider transaction report is specific to an executive's personal equity holdings and does not provide broader insights into industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may interpret insider selling, even if pre-planned, as a slight reduction in management's direct alignment with shareholder interests, though the 10b5-1 plan mitigates this concern.

Key Dates

Recommendation

The insider sales by George W. Lloyd, while significant in dollar value, were executed under a pre-arranged 10b5-1 plan. This suggests a planned liquidity event rather than a reaction to new company-specific negative news. Given the pre-planned nature and the executive's substantial remaining indirect holdings and exchangeable interests, this transaction alone does not warrant a change in investment thesis. Investors should maintain their current position, monitoring future company performance and broader market conditions.

Keywords

Royalty Pharma, RPRX, Insider Trading, Form 4, Share Sale, George W. Lloyd, 10b5-1 Plan, Executive Compensation, Equity Sales